

Index

- A disintegrin and metalloproteinase* (ADAM), 566–567, 570–574, 577–580
- A disintegrin and metalloproteinase with thrombospondin repeats* (ADAMTS), 567, 569–573, 577
- Acetyltransferase coenzyme A2, 275
- Acetyltransferase Tip60, 275
- aCGH, 273–274
- Actin, 223
- ADP-bound form, 226, 230
 - ATP-bound form, 226, 227, 230
 - filamentous (F-), 225
 - globular (G-), 225, 228
 - γ -isoform, 225
 - polarity of, 226–228
 - polymerization of, 226, 238
- Actin filament (F-actin)
- barbed end of, 228, 230, 231
 - double helix of, 225
 - pointed end of, 228, 237
 - treadmill of, 225
- Actin polymerization, 228, 230–232, 238
- critical concentration of, 225, 226
 - elongation phase of, 226, 227
 - equilibration phase of
 - nucleation phase of, 226, 227
- α -actinin, 234, 238
- EF-hand structure of, 233
 - F-actin crosslinking activity of, 231, 233
- Activity-dependent neuroprotective protein (ADNP), 674–677, 680, 681
- Activity-dependent neurotrophic factor, 674
- ADNF-14, 675, 676, 678
 - ADNF-9, 675–682, 684
 - SAL, 676–684
- Adenylyl cyclase, 270
- ADF/Cofilin, 229
- Adhesion molecules, 285, 286, 290
- L-selectin, 288, 291–294, 297
 - peripheral node vascular addressin (PNAd) 284, 291–293
 - P-selectin, 284, 291, 294
 - P-selectin glycoprotein ligand 1 (PSGL-1), 284, 291, 293, 294
 - sulfoadhesin, 294
- Adseverin, 228
- Advillin, 228
- Aggrecanase, 570
- Aggregates, 659
- Aggregation, 356, 357, 360–364, 366
- Aging, 659
- Aging pigment, 666
- Atg7* mice, 668
- ALCAM, 4, 80–83, 108, 111
- Allan-Herndon-Dudley syndrome, 267
- Alzheimer's disease (AD), 214, 347, 349, 447, 448, 470, 473, 578, 579, 592, 593, 601, 604, 606, 658, 659, 674, 681–684
- amyloid peptides, 454, 675, 678, 679, 682
 - calpain proteolytic system, 455
 - conversion of p35 to p25, 455
 - dementia, 454
 - hippocampal neurons, 454–456
 - plaques and tangles, 454
 - sporadic AD (SAD) or familial AD (FAD), 595, 605
- AMICA, 41, 53, 55–57
- Aminopeptidase, 626, 629–640, 642, 643
- Ammon's horn sclerosis (AHS), 198, 210, 213
- Amyloid, 578–579
- Amyloid β (A β), 578, 592
- A β degradation, 594, 596, 598, 605, 606
 - A β fibrillation, 596
- Amyloid peptide, 659
- Amyloid peptide, A β , 470
- Amyloid precursor protein (APP), 470, 473–484, 486–493, 495–497, 570
- α -secretase, 578
- Amyloid precursor, 275
- Amyloidosis, 327
- Amyotrophic lateral sclerosis (ALS), 195, 214, 448
- glutamate toxicity, 455
 - Lou Gehrig's disease, 455
 - motoneuron degeneration, 455
 - oxidative stress and Ca²⁺ influx, 455
- Anaphase-promoting complex, 656
- Angelman's syndrome, 266
- Angiogenesis, 295, 576, 577
- angiogenic switch, 294, 296
- Angiotensin II-specific, 269
- Angiotensin, 626, 629, 633, 634, 641, 643
- APC, 656
- Apolipoprotein E, 330, 596, 629, 678
- Apoptosis, 658, 659
- death receptor-mediated pathway, 518, 519, 525, 526
 - endoplasmic reticulum-mediated pathway, 526–528
 - mitochondrial pathway, 521, 522, 529
 - morphological and biochemical features, 516, 517, 519, 520, 530
 - role of caspases, 530
- Apoptosis-inducing factor (AIF), 517
- participant in DNA degradation, 520, 521
 - release from mitochondria in apoptosis, 520, 530
 - role in caspase-independent apoptosis, 530
- Apoptosome, 520

- Apoptotic protease activating factor (Apaf)-1, 517
 – role in caspase-9 activation, 520, 521
- Arginine vasopressin, 270
- Argininosuccinase, 264
- Aristaless-related homeobox, 266
- Arp2/3 complex
 – F-actin branching activity of, 232, 238
 – increase of polymerization point, 231, 232, 238
 – N-WASP binding of, 231, 232, 238
- Array comparative genomic hybridization, *See* aCGH
- ARX protein, 266
- Aspartic proteases inhibitors
 – pepstatins, 606
- Atg5, 668
- Atg7 mice, 668
- Autism, 261, 271, 272, 276
- Autofluorescence
 – as property of lipofuscin, 666, 667
- Autophagosomes, 665
 – role in garbage catastrophe, 664, 666–668
- Axon
 – elongation, 657
 – guidance, 657
 – initiation, 657
 – regeneration, 656
- $A\beta$ peptides, 552–554, 558
 – intracellular degradation of, 555, 556
 – extracellular degradation of, 559
- BAPTA, 200–203, 205, 210
- Bcl-2 family, 529
 – Bcl-2 homology (BH) domains, 522, 523
 – member subclasses, 522, 523
 – overexpression as potential therapeutic agent, 534
 – regulation of apoptosis, 521–523
- Bestatin, 633, 636, 637, 640, 642–644
- Biogenesis, 154, 155, 161, 162
 – dense-core secretory granules, 163, 164
- Bipolar disorder, 212
- Blood-brain barrier, 574–576, 578–580
- Brain peptidase, 626
- Brain tumors, 592, 602, 603, 605
- Brain-derived neurotrophic factor, 158
 – activity-dependent secretion of, 154
 – carboxypeptidase E, sorting receptor for, 157
 – sorting signal in, 155–157
- Branched-chain α -keto acid dehydrogenase (BCKAD), 263, 264, 276
- Ca^{2+} binding proteins, 447
- Ca^{2+} extrusion and sequestration, 448
 – Ca^{2+} -ATPase, 449, 450
 – energy depletion, 450
 – mitochondrial sequestration of Ca^{2+} , 450
- Calbindin D-28k (CB), 198, 205–208, 451, 456
- Calcium
 – binding protein, 198–215
 – buffer, 200–205
 – sensor (modulator), 198–200, 204
 – signaling, 198, 204, 208, 210, 215
- Caldesmon
 – calmodulin binding of, 234
 – inhibit actin polymerization promoting activity of N-WASP, 231, 232, 238
 – tropomyosin binding of, 234
- Calmodulin (CaM), 198, 199, 205, 451
- Calpain, 559, 560, 657
 – cerebral ischemia, 20
- Calpain activation, 457, 459
 – failure of energy-dependent mechanisms, 458
 – inhibition, 451–456, 458
 – intraneuronal Ca^{2+} overload, 449, 451
 – multiple mechanisms, 447–449, 458
- Calretinin (CR), 198, 199, 205, 276
- CAM, 56, 59–61, 63, 66, 69, 72, 77, 79, 80, 85, 86, 88, 90, 97, 99, 101, 103, 105–108, 111–113, 115, 117–119
- CapG, 228
- Carboxypeptidase E, 158, 159
 – association with lipid rafts, 157, 160, 162
 – amphipathic α -helix, 157, 160
 – *CPE^{fat/fat}* mice, 157
 – knock-out mouse, 157
 – sorting receptor for neuropeptides and BDNF, 157
 – transmembrane protein, 157, 160
- Carboxypeptidase, 626, 628–632, 634, 641
- Caspases, 560, 561
 – activation in cell death, 517, 519
 – cellular substrates, 529, 533
 – competitive inhibitors as potential therapeutic agents, 533, 534
 – domain structure, 517, 518
 – family subclasses, 517–519
 – non-apoptotic functions, 530
- Caspr, 41, 102, 103, 112
- Catalytic β -subunits, 657
- Cathepsins, 553–556
 – alterations in aging, 666
 – role in lysosomal degradation, 664, 665, 667
- c-Cbl, 656, 657
- cCGH, 273
- CD47, 49–53, 63–66
- cDNA array, 274
- Cell adhesion L1-like, 266, 272
- Cell adhesion molecule (CAM), 41–43, 46, 55, 56, 59–61, 63, 66, 69, 72, 77–80, 85, 86, 88–90, 96, 97, 99, 101, 103, 105–108, 111–115, 117–120
- Cell death, 658, 659
- Centenarians, proteolysis in, 666
- Central nervous system (CNS) trauma
 – behavioral recovery, 534, 536
 – brain injury, caspase activation, 531, 533
 – ischemic brain injury (stroke), 531
 – neuroprotection, 530, 535, 536
 – rodent models, 531–533
 – spinal cord injury, 532, 543
 – therapeutic strategies, 533, 534
- Central nervous system (CNS), 198–200, 205, 206, 212, 215, 296
 – axonal guidance, 298
 – injury, 297, 298
- CEPU-1, 41, 79
- Cerebral amyloid angiopathy (CAA), 592, 593, 595, 596, 601
- Cerebral infarction, 597, 601
 – cerebrovascular deposits (CD), 470
- Chaperone, 270, 378, 384, 388, 392, 394, 396, 654
 – heat shock stress, 390
- Chemokine receptors, 284, 290, 291, 293
- Chemokines, 285, 295, 566–568, 573, 574, 580
- CHL1, 41, 105–108, 110, 112, 113
- Cholesterol
 – cholesterol-sphingolipid-rich membrane microdomain, 157
 – dense-core secretory granules, 160, 162–164
 – lathosterolosis mouse, 161, 162
 – lipid rafts, 157, 160, 162, 164
 – Smith-Lemli-Opitz syndrome, 161

- Chromogranin A
 - assembly factor, 154, 162
 - controlling stability of granule proteins, 163
 - degradation of granule proteins, in the absence of, 163, 164
 - depletion of, 161, 163
 - granulogenic role of, 162, 163
 - regulation of dense-core secretory granule biogenesis by, 163, 164
- Chronic inflammation, 291–293
- cis*-interactions, 44, 47, 49, 51, 69, 70, 75, 90, 91, 117
- CLMP, 41, 53
- CLN1, 664, 665
 - mutation in NCL, 667
- Collagenase, 568
- Comparative genomic hybridization, *See* cCGH
- Conformational change, 654
- Congenital disorders of glycosylation, 264, 265
- Congo red, 396
- Contactin, 101–105, 114
- Convertase, 626, 631, 632
- Converting enzyme, 626, 629
- 20S core, 655
- Creatine defects, 262, 263
- Creatine kinase, 276
- CREB, 268
- CRE-binding, 268
- Creutzfeldt-Jakob disease, 601
- Crinophagy, 665
- CTX, 41, 53–55, 58, 70
- CXADR, 41, 53–58
- Cyclin D1, 659
- Cyclin dependent kinase-like, 271
- Cyclosporin A, 535
- Cysteine proteases inhibitors, cystatins, 601
 - kininogens, 599, 600
 - stefins, 599, 603
- Cystic fibrosis transmembrane conductance regulator, 391
- Cytochrome b_s, 276
- Cytochrome c, 517, 523, 526–528, 531, 532, 534, 536
 - release from mitochondria in apoptosis, 520–522
 - role in caspase-9 activation, 520, 521
- Cytoskeleton, 176, 178
- Cytotoxic proteins, 659
- Dasm1, 119
- DCC, 41, 99, 100, 120
- Death-inducing signaling complex (DISC), 526
- Death receptors, 526
 - apoptotic pathway, 521, 522, 529, 530
 - caspase activation, 528
- Degenerative disease, 626
- Degradation products, 655
- 3p Deletion syndrome, 272
- Dendrite, 170–176, 178–188
- Dendritic cells, 293
- Dendritic growth, 656
- Dendritic spine, 170
- Dense-core secretory granule
 - aggregation of cargo proteins in, 162, 163
 - biogenesis of, 163
- Deubiquitinating enzymes, 654, 655, 669
 - association with neurodegeneration, 668
- Dihydropteridine reductase, 262
- Dipeptide-inhibitor, 656
- Disaggregation, 658
- DJ-1, 658
- Down syndrome, 261, 275, 592
- Drebrin
 - inhibit fascin activity, 232
 - inhibit myosin activity, 234, 235–238, 255
 - inhibit tropomyosin binding to F-actin, 234
- DSCAM, 41, 113–117
- DSCAML1, 41, 113–116
- DUB, 655, 656
- E6-AP, 658, 659
- 4E-BP1, 10, 12, 16, 19, 24
- E-cadherin, 271
- EF-hand, 198–201, 215
- EGFR, 42, 64
- EGTA, 205, 210
- eIF2, 4–6, 9, 13, 14, 16–21, 24
- eIF2B, 9, 12, 16, 17, 19–21
- eIF4G, 4–7, 10, 11, 13, 14, 16, 17, 19–21, 23
- Endocytosis, 654–657
 - age-associated change in, 665
- Endonuclease G (Endo G), 517
 - participant in DNA degradation, 520, 521
 - release from mitochondria in apoptosis, 520, 521
 - role in caspase-independent apoptosis, 530
- Endopeptidase, 626, 629, 630–632, 634
- Endoplasmic reticulum (ER), 174, 346, 519
 - apoptotic pathway, 526–528
 - cross-talk with mitochondria, 528
 - endoplasmic reticulum stress, 347, 351
 - unfolded protein response (UPR), 347, 348, 351, 352, 526
- Endoplasmic reticulum (ER) stress, 9, 14, 356, 359, 362, 658
- Endosomal membrane, 656
- Endothelial cells, 291–293, 295, 296
- Energy landscape, 308–310, 313–315, 318
- Enkephalin, 626–628, 630–636, 638, 641–644
- Epilepsy, 210, 212
- Epileptic seizure, 448, 597
 - abnormalities in electrophysiological activity, 456
 - hyperexcitability, 456
 - oxidative stress, 445, 456–458
 - oxygen-regulated protein-150 kDa, 447, 456
 - seizure-induced brain damage, 456
- Endoplasmic reticulum associated degradation (ERAD)
 - connection to cytoplasmic degradation, 667
- ESAM, 42, 53–55, 58, 133
- Excitotoxicity, 213, 214
- Executioner caspases, 518–520, 526, 527, 529
- Exogenous antigen presentation
 - class II-associated li peptide (CLIP), 552, 553
 - invariant chain (Ii), 453, 460
 - major histocompatibility complex (MHC) class II, 552, 553
 - ovalbumin (OVA), 553, 554
 - T helper cell hybridomas, 553
- Exopeptidase, 629, 630, 641
- Experimental allergic encephalitis (EAE), 575
- Extracellular matrix
 - collagen, 566–570, 572, 580
 - laminin, 569
 - proteins, 553–555
 - proteoglycans, 566, 568–570, 572
- F3, 41, 44, 61, 101–104, 107, 108, 111, 112
- Familial AD (FAD), 470
- Familial encephalopathy, 594, 597
- Fascin
 - C-kinase regulation of, 232
 - F-actin bundling activity of, 231, 232
 - formation of polarized F-actin bundle, 232
- Fetal alcohol syndrome, 678, 680

- Fetoprotein, 262
- FGFR, 42, 79, 91, 92, 94, 107–109, 134
- Fibronectin, 569, 579
- FISH, 272, 274
- FLRT, 42
- Fluorescence in situ hybridization, *See* FISH
- FMRI, 265
- FMRP, 265
- Fragile X mental retardation protein (FMRP), 175, 176, 185
- Fragile X syndrome, 265, 277
- Fucosylated, 265
- Fukutin, 272
- Fukuyama congenital muscular
– dystrophy, 271, 272
- G proteins, 267, 270
- GABA receptor $A\gamma 2$, *See* GABRG2
- GABRG2, 275
- GADD34 expression, 19, 24
- Galactokinase, 263
- Galactose-1-phosphate uridylyl transferase, 263
- Galactosemia, 263
- Garbage catastrophe, 664, 668
– proposed mechanism, 666, 667
- GDP dissociation inhibitors, 267
- GDP-fucose transporter, 265
- Gelatinase, 569, 580
– gelatinase A, 568, 575
– gelatinase B, 568
- Gelsolin
– calcium regulation of, 228
– F-actin capping activity of, 228, 229, 230, 234
– F-actin severing activity of, 228, 229
– nucleation promoting activity of, 228, 229
– PIP₂ regulation of, 228, 230
- Gene therapy, 536
- GGEL, 244, 246, 247, 251–253
- Glia, 566, 568, 575
– astrocytes, 569, 572, 573, 576–578, 580, 581
– microglia, 569, 572–574, 579
– oligodendrocytes, 576
- Glucocorticoids, 568
- Glutamate receptors
– α -Amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor, 447, 448
– Ca²⁺ influx, 448–450, 457
– endoplasmic reticulum, 448, 449
– ionotropic, 447, 448, 455, 457
– metabotropic, 447–449, 455
– N-methyl-D-aspartate receptor, 447, 448
- Glycolipids, 284, 286, 290, 298
– sulfatide, 296, 297
- Glycoproteins, 264, 284–286, 290, 291, 296, 298
– mucins, 293
- Golgi apparatus, 174, 189
- Granulogenic proteins, 162
- Growth cone dynamics, 657
- Growth cone, 225, 226, 232
– C-domain
– dynamics of, 236, 238
– filopodium, 228, 229, 231, 236–238
– lamellipodium, 228, 229, 231, 237–238
– P-domain, 236
- Growth factors, 284, 294–296
- GRP78, 276
- GSTO1, 276
- GTPase, 267, 268
- GTP-binding proteins, 267
- Guanidinoacetate methyltransferase, 262
- HADII, 263
- HDAC inhibitor, 265
- HECT domains, 654
- Helicase 2, 267
- Hemoglobin, 266
- Hereditary cerebral hemorrhage with amyloidosis (HCHWA), 595
– Dutch type (HCHWA-D), 592
– Icelandic type (HCHWA-I), 601
- Heterophilic interaction, 44, 59, 79, 107, 113, 118, 120
- High endothelial venules (HEV), 284, 291–292, 294
– extralymphoid HEV-like vessels, 293
- Hippocampus
– dentate gyrus, 569, 571
- Histone acetyltransferase, 268, 275
- Histones, 276
- HLA-DRB3, 275
- Holoprosencephaly, 269
- Homophilic interactions, 44, 47, 50, 56, 58, 60, 63, 69, 82, 85, 87, 90, 96, 99, 102, 104, 107, 111–113, 115, 118
- Hormone half-life, 290, 296
– lutropin, 284, 295
– thyrotropin, 284, 295
- HR6, 656
- Hsc73
– role in lysosomal degradation, 665
- HtrA2/Omi, 517, 530
– endogenous inhibitor of IAPs, 520
– release from mitochondria in apoptosis, 520
- Hunter syndrome, 264
- Huntingtin, 659
- Huntington's disease, 448, 668
– CAG repeat, 457
– chorea
– Huntington, 457
– neurodegeneration, 457
– polyglutamine disease, 457
– striatum, 457
- Hybrid proteasome, 378, 379
- Hydroxysteroid dehydrogenase, 263
- Hypoparathyroidism-retardation-dysmorphism syndrome, 270
- Iduronate sulfatase, 264
- IgLON, 42, 45, 77–80
- Ig-module, 44–51, 53–57, 60–63, 68, 70, 74, 76, 79, 82–84, 87, 89, 90, 92, 96, 98, 99, 101–102, 104, 107, 109, 112, 114–116, 118–120
- IGSF, 41–47, 75, 77, 120
- IGSF11, 53, 55, 56, 58, 59, 133, 149
- IGSF9, 42, 118, 119
- IL1RAP, 269
- Immediate early gene (IEG), 170, 178
- Immunoglobulin superfamily, 42–44, 46, 55, 73, 119
- Immunoproteasome
– LMP2, 376, 399
– LMP7, 376, 399
– LMP10, 376
- Inclusions, 659
- Inflammation, 568, 569, 572, 573, 578–580
- Inhibitor, 626, 629, 630, 633–644
- Inhibitors of apoptosis (IAP), 518, 528
– endogenous inhibitor of caspases, 520
– overexpression as potential therapeutic agent, 534, 535
- Initiation factors, 3–6, 8, 10, 11, 16, 17, 19
- Initiator caspases, 518, 519, 526, 528
- Insoluble aggregates, 659
- Insulin, 270
- Insulin-degrading enzyme, 559
- 7-Integrin, 272
- Integrin-associated protein, 49–53
- Interferon- β , 574
- Interleukin-1 receptor accessory, 269
- Interleukin-1 β , 573
- Internalization, 657
- Intracellular inclusions
– aggresomes, 373, 391, 396, 397
– centrosome, 387, 391, 392, 397
– degasome, 396
– γ -tubulin, 387, 390–392
– microtubules, 388, 391, 397
– neuronal intranuclear inclusions, 373, 384

- proteolysis center, 391, 396
- tubulin, 387, 388, 390–392
- Intracerebroventricular (ICV)
 - injections, 533, 534
- Ischemic brain injury
 - blockage of cerebral blood supply, 451
 - calpain inhibitor MDL-28170, 452
 - calpain-mediated proteolysis, 452
 - excitotoxicity, 451
 - ischemic penumbra, 451, 452
 - necrosis and apoptosis, 451
- Isovaleryl-CoA dehydrogenase, 276
- Kilon, 42, 77–79
- L1, 41, 42, 47, 75, 85, 87, 92, 103–113
- L1CAM, 266, 272
- Lactacystin, 658
- Lamin, 276
- Lamp2a, role in chaperone-mediated proteolysis, 665
- LC-MS/MS, 276–277
- Leukocyte recirculation, 291, 297
- Lewy bodies, 659
- Ligand-gated Ca²⁺ channels, 450
 - Ca²⁺ releasing channels, 449
 - IP₃ receptors, 448, 449
 - ryanodine receptors, 447, 449
- Ligase E3A, 266
- Lipid rafts, carboxypeptidase E, 158, 159
 - cholesterol-sphingolipid-rich microdomain, 157
- Lipofuscin
 - association with aging, 666
 - role in garbage catastrophe, 666, 667
- Lipopolysaccharide, 573
- Lissencephaly-1, 264
- LMP2
 - mouse knockout model, 668
- Long term depression (LTD), 170
- Long-term potentiation (LTP), 170, 171, 178, 182, 185–186
- Lymphoid organs
 - lymph nodes, 293
 - peripheral lymphoid organs, 291
- Lysosomes, 654, 664, 665, 667
- Macroautophagy, 665
- α -macroglobulins, 572, 593
- MAG, 41, 47, 56, 86–88
- Maintenance, 654, 656, 657, 659
- MALDI-TOF-MS, 275
- Malonyl-, Methylmalonyl-CoA
 - decarboxylase defects, 263
- Malonyl-CoA decarboxylase, 263
- MAPH, 274
- Maple syrup urine disease, 263, 264, 276
- MASA syndrome, 266
- Matrilysin, 569
- Matrix assisted laser desorption/ionization time-of-flight
 - mass spectrometry, *See* MALDI-TOF
 - MS, 275, 276
- Matrix metalloproteinase (MMP), 558, 559, 567, 570
 - collagenase, 568
 - gelatinase, 568, 569
 - matrilysin, 569
 - membrane-type MMP, 566–572
 - other MMPs, 569, 570
 - stromelysin, 569
- mDia1, actin polymerization promoting activity of, 231
- MECP2, 271, 276
- Melanoma cell adhesion molecule (MCAM), 41, 42, 83–86
- Metalloproteases inhibitors, 606
 - tissue inhibitors of metalloproteases (TIMP), 592, 604, 605
- Methyl CpG-binding, 271
- Methylmalonyl-CoA decarboxylase, 263
- MHC DR β 3, *See* HLA-DRB3
- Microdeletions, 268, 273, 274
- Microduplications, 273, 274
- Microglia, 552–556, 559, 560, 568, 569, 572–574, 579
 - activation of, 557, 558
 - apoptosis of, 561
- Microtubule, 659, 677, 682, 683
- Misfolding, 659
- Mitochondria, 356, 362, 363, 366, 535, 665
 - apoptotic pathway, 520–524
 - caspase activation, 528, 529
 - contribution to lipofuscin, 666
 - degradation by autophagy, 668
 - source of reactive oxygen, 667
 - cross-talk with endoplasmic reticulum, 522
 - cross-talk with nucleus, 520
 - dysfunction in apoptosis, 526
 - inhibition of permeability transition as potential therapy, 523, 524
 - release of pro-apoptotic factors, 520–523
- Molecular dynamics, 312, 313
- Molten globule, 310–332
- Monocarboxylate transporter-8, 267
- Monosomy, 273
- Mono-ubiquitination, 654, 656, 657
- Mov34 mice, loss of function in proteasome, 668
- Mowat-Wilson syndrome, 271
- mRNA, 170–176, 178, 180–189
 - structural elements, 6, 7
- mTOR, 3, 10–12
- Multiple sclerosis, 448, 593, 598, 600, 606
 - autoimmune inflammatory reaction, 458
 - demyelination, 458, 459
 - destruction of myelin proteins, 458, 459
 - experimental allergic encephalomyelitis
 - neurodegenerative component, 447, 459
 - white matter plaque, 458
- Multiplex amplifiable probe hybridization, *See* MAPH
- Multi-ubiquitination, 654
- Mutated proteins, 654
- Myelin protein zero, 41, 45–49
- Myelin-associated glycoprotein, 41, 42, 86–88
- Myosin
 - -I, 236
 - -II, 235–237
 - -III, 237
 - -V, 236
 - -VI, 237
 - Snell's waltzer deafness, 237
 - -VII, 237
 - Usher 1B syndrome, 237
 - -IX, 237
 - -X, 237
 - ATPase activity of, 234–236
 - coiled-coil structure, 235, 237
 - head domain, 235, 237
 - heavy chain, 235, 237, 238
 - IQ motif, 236, 237
 - light chain phosphorylation, 235, 236
 - neck domain, 235, 237
 - phosphorylation by myosin light chain kinase, 235
 - phosphorylation by rho kinase, 235
 - processive movement, 237
 - tail domain, 236, 237
- NAP, 676–684
- NCAM2, 42, 95–97
- N^ε-(γ -L-glutamyl)-L-lysine, 244, 246, 247
- Nectin, 42, 45, 66, 67, 72–77
- Nectin, 45, 66–72, 74–76
- Nectin-like, 71–77
- Neddd4, 657
- N-end rule, 656

- Netrin G1, 271
- Neural cell adhesion molecule (NCAM), 41–43, 47, 57, 63, 65, 75, 79, 85, 87–95, 108, 109, 119
- Neurite outgrowth, 656, 657
- Neurodegeneration, 249, 253, 254, 356, 363, 366, 659
- Neurodegenerative disease
 - β -amyloid in, 346
 - polyglutamine disease, 349, 350
 - prion disease, 350
 - synuclein in, 349, 350
 - tau in, 346–349
- Neurodegenerative, 214
- Neurofascin, 42, 102–108, 110–112
- Neurological diseases, 566
 - Alzheimer's disease, 570, 578, 579
 - amyotrophic lateral sclerosis, 581
 - glioma, 577, 581
 - anaplastic astrocytomas, 576
 - glioblastoma multiforme, 576
 - human immunodeficiency virus dementia (HIVD), 579, 580
 - multiple sclerosis, 572, 574, 575
 - Parkinson's disease, 571
 - polyglutamine disease, 581
 - stroke (cerebral ischemia), 575, 576
- Neuron, 200, 201, 204–212, 214, 215, 654–659
- Neuronal calcium sensor (NCS), 199
- Neuronal ceroid lipofuscinoses, 667
- Neuronal development, 655–657
- Neuronal survival, 659
- Neuropeptidase, 626, 644
- Neuropeptides, 161, 626–638, 640
 - regulated secretion of, 157–159
 - sorting signals in, 154–157, 164
- Neuroplastin, 59, 60
- Neurotoxicity, 578, 579
- NMDA receptor complex (NRC), 170, 176
- NMDA receptors, 557
- Nope, 42, 119, 120
- NrCAM, 42, 82, 83, 102–108, 110–112, 119
- N-WASP
 - actin polymerization promoting activity of, 231, 232, 238
 - Arp2/3 binding of, 231, 232, 238
 - Cdc42 regulation of, 231
- OBCAM, 42, 77–80
- OCAM, 42, 95
- Oligonucleotide arrays, 274, 275, 277
- Oligophrenin, 267
- Opioid peptide, 630, 634, 644
- Ornithine transcarbamylase, 264
- Oxidative damage, 659
- P0, 45, 47–49, 63, 78, 85, 87
- p21-activated kinase, 268, 269
- P2X₇ receptors, 560, 561
- PA200, 379
 - ARM/HEAT repeats, 377
- PAK proteins, 268
- Palmitoyl protein thioesterase-1, mutation in NCL model, 667–669
- Parkin, 658
- Parkinson's disease, 447, 448, 596, 658, 659
 - degeneration of dopaminergic neurons, 457
 - Lewy bodies, 458
 - movement disorder, 457
 - substantia nigra, 457, 458
 - α -synuclein, 458
- Partington syndrome, 266
- Parvalbumin (PV), 198, 199, 205–215
- Patched, 269
- PDGFR, 42, 64, 76
- PDZ, 42, 56–58, 67, 68, 70, 74, 76, 111, 118, 119
- Peptide
 - degradation, 374
 - processing, 632
- Peroxisomes, 665
- PGP9.5, 659
- Phenylalanine hydroxylase, 262
- Phenylketonuria, 261
- Phosphoadenosine-5'-phosphosulfate (PAPS), 284, 286
 - PAPS synthase, 287
- Phosphomannomutase, 261
- Phosphorylation, 654, 657
- PI31, 658
- PKU. *See* Phenylketonuria
- Plasmin, 556–558, 560
- Plasminogen activators, 556–558, 560
- Platelet-activating factor acetylhydrolase, 264
- Poliavirus receptor-related, 42, 66, 68
- Polyamines, 244, 249, 252
- Polyglutamine expansion diseases, 391
 - ataxin-1, 393, 395, 397, 398
 - ataxin-2, 394
 - CAG repeat, 393, 394
 - dentatorubral pallidolusian atrophy, 393–394
 - Huntingtin, 381, 385, 386, 393–399
 - Huntington's disease, 373, 380, 386, 390, 393, 396, 397, 399
 - Machado-Joseph disease, 393
 - polyQ tract, 393–399
 - spinobulbar muscular atrophy (Kennedy's disease), 393
 - spinocerebellar ataxias, 373, 393
- Polyglutamine, 357–366
 - binding, 265, 266
- Polypyrimidine-tract binding protein
 - dense-core secretory granule biogenesis, 161–164
 - post-transcriptional mechanism, 164
 - stability of mRNAs encoding granule proteins, 164
- Polyribosomes, 170–174, 180, 186, 188
- Poly-ubiquitination, 654
- Postsynaptic density, 180, 182
- Prader-Willi syndrome, 265, 266
- Presenillin, 391
- Procaspase, 517, 519, 520, 526, 528, 529, 535
- Process outgrowth, 659
- Procollagen N-proteinases, 567, 570
- Profilin, 226, 229
 - ATP/ADP exchange, 230
 - sequestering activity of, 230
- Progressive myoclonus epilepsies (PME), 603
- Prohormone convertase 1/3, 164
 - amphipathic α -helix in, 160
 - association with lipid rafts, 160
 - C-terminus of, 160
 - cytoplasmic tail of, 157, 158
 - pro-domain of, 160
 - sorting information in, 160
 - trafficking of, 157
 - transmembrane protein, 160
- Prohormone protease, 632
- Proinsulin
 - carboxypeptidase E, 157, 158
 - hexamerization of, 155
 - sorting signal in, 155–157
 - sorting to regulated secretory pathway, 154, 156, 158, 159
 - X-ray crystal structure of, insulin, 155, 156
- Proopiomelanocortin, 154
 - carboxypeptidase E, 157–159
 - NMR structure for, 155
 - sorting signal in, 155, 157
- Pro-protein convertase, furin and furin-like proteases, 568, 571
- Protease catalytic mechanism, 410–413
- Protease classification of proteases, families and clans, 410, 411
- Protease, human trypsin 4, 411, 430, 434, 435
 - biochemical characterisation of 4, 431–433
 - peptide substrates, 433
 - pH-jump activation, 432
 - polypeptide substrate, 433

- reaction with MUGB, 432
- resistance to canonical inhibitors, 433
- restricted substrate specificity, 413, 433
- small synthetic substrates, 432, 435
- chromosomal localization, 414, 428, 429
- expression in different areas of brain, 429–431
- immunohistochemical localization, 431
- isoforms of human trypsin 4, 428, 429
 - alternative splicing, 419–425
 - alternative transcription initiation, 429
 - CUG start codon, 428, 429
 - leader peptide, 428–431
 - leucine as the initiator amino acid, 429
 - 5'RACE PCR, 429
 - regulation of expression level, 417, 419, 429
- potential roles in the CNS, 426, 427
 - Alzheimer's disease, 410, 418, 427
 - cancer, 413, 425, 426
 - cell migration, 413, 416
 - metastasis, 426, 434
 - migration of GnRH neurons, 434
 - multiple sclerosis, 410, 426
 - myelin degradation, 427
 - PAR activation, 433
 - tumour suppression, 427
- structure of human trypsin 4, 411, 412, 432
 - activation peptide, 418, 425
 - Arg193 (S2' subsite), 432
 - disulfide bridges, 412, 413
 - leader peptide, 428–431
 - oxyanion hole, 411, 432, 433
 - substrate binding site, 412
- Protease, kallikreins, 420
 - alternative splicing, 419, 425
 - association of kallikreins with diseases
 - cancer, 425, 426
 - hypertension, 426
 - pathological keratinization, psoriasis, 426, 427
 - renal nephritis, 426
 - serum tumor biomarkers, 425, 426
 - biological roles of kallikreins, 426
 - activation of uPA and plasminogen, 410, 413
 - inflammation, 413, 426, 433
 - ischemia, 425, 427
 - processing biologically active peptides, 425
 - regulation of blood pressure, 425
 - chromosomal localization, 414, 428, 429
 - classification, plasma and tissue kallikreins, 410
 - expression in central nervous system, 428
 - gene structure of kallikreins, 418
 - potential roles of kallikreins in the central nervous system
 - Alzheimer's disease, 427
 - demyelination, 426, 433
 - experimental autoimmune encephalomyelitis, 410, 426
 - frontotemporal dementia, 410, 428
 - glutamate-receptor mediated cytotoxic injury, 426
 - hippocampal networking, 427
 - hippocampal plasticity, 427
 - long-term potentiation, 410, 416
 - multiple sclerosis, 410, 426
 - multiple system atrophy, 410, 426
 - myelination, turnover of myelin protein, 426
 - neural plasticity, 427
 - neurite outgrowth, 416, 427, 435
 - neuronal development, 427
 - neuroprotection in ischemia, 427
 - Parkinson's disease, 410, 426, 427
 - production of cerebrospinal fluid, 427
 - regulation of seizures, 427
 - synaptogenesis, 427, 435
 - synucleinopathies, 426, 427
 - regulation of catalytic activity, 411
 - regulation of expression, steroid hormones, 419
 - sequence homology among kallikreins, 418, 419, 426
 - structure of kallikrein enzymes, 418
 - activation peptide, 418, 425
 - disulphide bridges, 412
 - kallikrein loop, 425
 - signal peptide, 411, 418, 425
 - substrate binding site, 412
- Protease activated receptors (PAR), 414, 425, 433, 434
 - activation of PARs by proteases and, 416
 - expression of PARs in central nervous system, 415, 416
 - induction of cell death, 417, 418
- Protease, plasma serine
 - activity and specificity of haemostatic serine proteases, 413, 414
 - blood clotting, 413
 - brain damage, 417
 - chromosomal localization of haemostatic serine proteases, 414
 - coagulation cascade, 413, 414
 - role of plasma serine proteases in the CNS, 417–418
 - development, 413–416
 - neuronal survival, 416
 - plasticity, 416
 - thrombin
 - Alzheimer's disease, 418, 427, 428
 - expression in different tissues, 415, 416
 - facilitation of long-term potentiation, 416–418
 - induction of apoptosis, 418
 - induction of edema, 418
 - neuronal excitability, 418
 - structural basis for the restricted specificity, 413, 414
 - plasmin, 411, 413, 414, 416
 - urokinase-type plasminogen activator (uPA), 414, 415
 - cell migration, 413, 416
 - expression in central nervous system, 413
 - potential natural substrates of uPA, 413, 414
 - substrate specificity of uPA, 413, 414
- tissue-type plasminogen activator (tPA)
 - activation of plasminogen by tPA, 413, 414
 - axonal rearrangement, 416
 - expression in central nervous system, 414
 - long-term potentiation, 416–418
 - migration of neurons, 416
 - neurite outgrowth, 416, 427, 435
 - synaptic plasticity, 416, 427

- Protease, serine, 409
- activation domain, 411
 - activation peptide, 418, 425
 - biological functions of serine proteases, 432
 - catalytic triad (His57, Asp102, Ser195), 412, 425, 432
 - exon shuffling, 412, 414, 418
 - mechanism of action, 416
 - protease domain and additional structural domains, 411–414, 418, 425, 429–431
 - signal peptide, 411, 418, 425
 - specific subsites (Schechter-Berger nomenclature), 412
 - structural change during activation, 432
 - substrate specificity, 412, 413, 418, 425, 433
 - tertiary structure of the protease domain, 410
 - active site, 411–413, 425, 432, 433
 - β -barrel, 411, 425
 - disulfide bridges, 412, 413
 - oxyanion hole, 411, 432, 433
 - substrate binding site, 412
- Proteasomal activity, 656–659
- Proteasomal subunits, 657, 659
- 20S proteasome, 377, 379, 382–385, 392, 393, 395, 396, 398
- α -type subunits, 374, 376, 378
 - β -type subunits, 374–376
 - chymotrypsinlike activity, 375
 - N-terminal threonine nucleophile, 373, 375
 - peptidylglutamyl peptide hydrolyzing activity, 375
 - trypsinlike activity, 389
- 26S proteasome, 387–398
- Proteasome and Parkinson's disease, 383–390
- autosomal recessive juvenile parkinsonism, 373, 387
 - CDCrel-1, 387, 388
 - Parkin, 386, 387
 - Parkin-associated endothelin receptor-like receptor (Pael-R), 388
 - phospholipase D, 385
 - synaptogamin XI, 388
 - α -synuclein, 389, 390
 - synphilin-1, 386, 389, 390
 - tyrosine hydroxylase, 384, 389, 390
- Proteasome inhibitor(s), 384, 391, 394, 398, 399, 657, 658
- epoxomicin, 385, 390
 - lactacystin, 374, 385, 387, 389, 390, 392, 395, 396
 - MG132, 375, 389
 - Z-Ile-Glu(O-tBu)-Ala-leucinal (PSI), 373
- Proteasome(s), 350, 351, 359, 361, 363, 558, 655, 657–660, 667, 669
- age-related changes, 665, 666
 - assembly of, 666
 - in centenarians, 666
 - mouse mutations, 668
 - ubiquitin proteasome system, 654
- Protein
- accumulation, 659
 - cross links, 244, 254
 - folding, 303
 - synthesis, 170, 171, 173, 186–189
- Proteinases activated receptor-1 (PAR-1), 568, 578, 579, 581
- Protein phosphatase 1, 3, 18
- Protein-protein interactions
- caspase-recruiting domain (CARD), 518, 520, 529
 - death domain (DD), 518, 525, 526, 529
 - death effector domain (DED), 518, 519, 526
- Proteoglycanase, 567
- Proteoglycans, 285–287, 290, 294, 296–298, 568
- aggrecan, 566, 567, 569–571, 573
 - brevican, 566, 571–573, 577
 - chondroitin sulfate proteoglycans, 284, 297
 - heparan sulfate proteoglycans, 284, 294, 298
 - neurocan, 566
 - versican, 566, 571, 573
- Proteomics, 275, 276
- Protofibrillary form, 660
- Pruning, 656
- PTPNS1, 42, 47, 50–52, 61–66
- Punc, 42, 119, 120
- Purkinje neurons, 668
- sensitivity to stress, 669
- Puromycin, 626, 629, 635–637, 639, 642–644
- PVR, 42, 66, 68, 69, 71–73
- RAS suppressor, 275
- Reactive oxygen species, 654, 658
- Receptor tyrosine kinases, 656
- Receptor, 269, 270
- Regulated intramembrane proteolysis (RIP)
- γ secretase complex (γ SC), 471, 475, 476, 483–493
 - isolation, 485, 486, 495, 497
 - specificity, 487
 - inhibition, 192, 489, 490
 - nicastrin (NCT) (aph-2), 470, 471, 475, 483–485, 495
 - aph-1, 471, 483, 484, 491, 495, 496
 - pen-2, 471, 483–485, 491, 495
- Regulated secretory pathway, 156, 158, 159
- in endocrine cells, 154, 155
 - in neuroendocrine cells, 154
 - sorting of neuropeptides and BDNF to, 155–157
 - sorting receptors for, 155, 164
 - sorting signals for, 155, 166
- 11S regulator, 376
- 19S regulatory complex, 377–379, 382, 394, 396
- Renpenning syndrome, 265
- Rett syndrome, 271, 276
- Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), 572
- Rho GEF6, 268
- Rho GTPases, 267, 268
- Rho guanine nucleotide exchange factors, *See* Rho GEF
- Ribosome, 170–174, 180, 181, 187, 188
- RNCAM, 42, 96
- Robo, 42, 43, 97–101
- ROS, 658
- Rubinstein-Taybi syndrome, 268
- 19 S cap complex, 379
- μ -particle, 377, 378
 - AAA ATPase, 378
 - PA700, 392
 - regulatory particle triple A protein (Rpt), 378
 - regulatory protein non-ATPase (Rpn), 378
 - Rpn 1, 378
 - Rpn 2, 378
 - Rpn 10 (S5a), 378, 394
 - Rpn 11, 378, 382
 - Rpt 5 (S6'), 378, 385
- Schizophrenia, 212, 215
- SDK1, 42, 116–118
- SDK2, 116–118
- Secretases, 470–472, 475, 476, 478, 479, 492, 496, 497
- α -Secretases (K^{16L}¹⁷ cleavage)
- ADAM, 471, 475, 476, 478, 489–497
 - TNF- α -converting enzyme (TACE), 471
 - characterization, 475, 476

- domains, 476, 477
- tissue inhibitors of metalloproteases (TIMP), 478
- therapeutics, 479
- β*-secretases, *β*-APP-converting enzymes (BACE), 479
 - characterization, 480, 481
 - domains, 480
 - pharmacology, 481–483
 - specificity, 481
- Secretory granule proteins, 155
 - degradation of, 157, 163, 164
 - stability of, 163
- Senile plaque, SP, 470
- Serine protease inhibitors
 - α_1 -Antichymotrypsin (ACT), 592, 595
 - antithrombin, 597, 598
 - neuroserpin, 592, 597
 - pigment epithelium-derived factor (PEDF), 598
 - plasminogen activator inhibitor (PAI), 598
 - protease nexin I [Glia-derived nexin (GDN)], 595, 596
 - protease nexin II [Amyloid precursor protein (APP)], 594
- Sheddase, 566, 577, 578
 - ectodomain shedding, 569, 570, 581
- SHPS-1, 43, 61
- Signal-regulatory proteins, 60
- Signal transduction, 173, 179, 180, 182, 184, 185
- Slit-Robo GTPase, 268
- Smac/Diablo, 517, 534, 535
 - endogenous inhibitor of IAPs, 520
 - release from mitochondria in apoptosis, 520
- Smad interacting, 271
- Small nuclear ribonucleoprotein, 266
- Smurf1, 656
- SNP analysis, 275, 276
- Sonic hedgehog, 269
- Sorting receptor
 - carboxypeptidase E, 157–159
 - for BDNF
 - for proinsulin, 155–157
 - for proopiomelanocortin, 155
- Sorting signal, 159
 - acidic amino acids in, 154
 - hydrophobic amino acids in, 155, 156
 - in BDNF, 155
 - in proinsulin, 155, 157, 158
 - in proopiomelanocortin, 155
- Spinal cord injury, 447, 448, 459
 - calpain activation and neurodegeneration, 453
 - calpain inhibitors for neuroprotection, 453
 - devastating secondary injury process, 452, 453
 - increases in intracellular free Ca^{2+} levels, 452, 453
 - pathophysiology, 452, 453
 - primary injury, 452
- Spine apparatus, 172, 174
- Spinocerebellar ataxia type 1, 659
- Spinocerebellar ataxias, 668
 - sporadic AD, SAD, 474
- Stearyl-Nle17-VIP
 - SNV, 674, 675, 677
- Stromelysins, 569
- Substrate targeting for ubiquitination, 382
 - cyclin, 381
 - N-end rule, 381
 - PEST sequence, 381
 - phosphorylation, 381
- Sulfatases, 285
 - lysosomal, 287
 - endo-sulfatases, 284, 287, 298
 - SULF1, 294–296
 - SULF2, 294–296
- Sulfate channels, 286, 287
- Sulfotopes, 284–287, 290, 298
 - antithrombin binding site, 294
 - growth-factor binding and sequestration, 295
 - viral docking sites, 291
- Sulfotransferase inhibitors, 293
- Sulfotransferases, 292, 293
 - cytosolic sulfotransferases, 288
 - role in detoxification and steroid metabolism, 284, 287
 - golgi-associated sulfotransferase, 284
- SUMO, 654, 658
- Synapse, 170–174, 178–189, 578
- Synapse-associated polyribosome complex (SPRC), 170, 174
- Synaptic plasticity, 659
- Synaptodendrosomes, 173, 175, 178, 186
- Synaptoneurosome, 173, 175, 186
- Syndecan, 566–578, 580
- α -synuclein, 658
- TAG-1, 45, 47, 63, 75, 83, 91, 92, 103, 104, 107, 111, 112
- Tandem mass spectrometry/mass spectrometry, *See* LC-MS/MS
- Targeting signal, 654
- Tau, 682, 683
- α -thalassemia, 266, 267
- Therapy, 363, 365
- Thrombin, 556–558
- Thrombospondin, 566, 567, 570, 571
- Thrombotic thrombocytopenia purpura, 570
- Thymosin β , 226, 231, 238
 - sequestering activity of, 230
- Tick-borne encephalitis, 593
- Tissue inhibitors of metalloproteases (TIMP), 552, 558, 567, 572
- TMEM25, 43, 119, 120
- Trafficking, 657, 658
- Transcription, 356–359, 361–363, 365, 366
- Transforming growth factor β , 410, 425
- Transglutaminases, 244, 245
- trans*-interactions, 44, 47–49, 51, 56, 58, 65, 69–71, 75, 77, 79, 80, 82, 85, 88, 90–93, 99, 100, 104, 107, 110, 111, 115
- Translation, 170–174, 176, 178, 180, 183–187, 189
- Translation regulation, 3, 12, 16, 21
- Transport, 170, 172–174, 178, 179, 182, 184, 190
- Traumatic brain injury, 448
 - Ca^{2+} channel blockers, 453
 - diffuse brain injury, 454
 - fluid-percussion brain injury, 454
 - involvement of calpain and caspase-3, 454
 - loss of cytoskeletal proteins, 454
 - pathophysiological pathways, 453
- Tropomyosin, 232, 233
 - caldesmon binding of, 234
 - increase the stability of F-actin, 234
 - inhibit the ADF/cofilin activity, 229, 234, 238
 - inhibit the drebrin activity
 - inhibit the fascin activity, 234
 - inhibit the gelsolin activity, 234
 - inhibit the myosin activity, 235
 - isoforms of, 234
- Tumor necrosis factor, 569
- Tumor necrosis factor converting enzyme (TACE), ADAM17, 569, 574, 578
- Ubiquitin carboxy-terminal hydrolases, 655, 658
- Ubiquitin elongation factor, E4
 - CHIP, 373, 382, 388

- U-box protein, 382
- Hsc70, 373, 382
- Ubiquitin hydrolase
 - deubiquitinating enzyme, 378, 382
 - PGP 9.5, 382
 - ubiquitin C-terminal hydrolase (UCH), 382
 - UCHL-1, 382
 - ubiquitin specific processing protease (UBP), 382
- Ubiquitin ligase, 654–659
- Ubiquitin ligation pathways, 656
- Ubiquitin pools, 668–670
 - contribution to neuronal sensitivity, 667
- Ubiquitin, 383, 385, 390–396, 654–659
 - anaphase promoting complex, 381
 - Angleman's syndrome, 381
 - HECT domain, 381
 - ring finger, 381, 386
 - SCF complex, 381
 - ubiquitin activating enzyme, E1, 380, 382
 - ubiquitin conjugating enzyme, E2, 381, 382, 394
 - UbcH7, 386, 388
 - UbcH8, 386, 388
 - ubiquitin-protein ligase, E3, 373, 381, 387
 - VBC complex, 381
- Ubiquitin-activating enzyme, 654
- Ubiquitination, 654–659
- Ubiquitin-binding subunits, 655
- Ubiquitin-conjugates, 656
- Ubiquitin-conjugating enzymes, 654
- Ubiquitin-independent proteolysis
 - cyclin-dependent kinase inhibitor p21^{cip1}, 382
 - microtubule associated protein tau, 383
 - ornithine decarboxylase, 373, 379, 382
- Ubiquitin-interacting motif
 - ubiquitin-binding protein, 391, 394
 - ubiquitin conjugating enzyme E2-25K, 394
 - valosin-containing protein, 394
- Ubiquitin-specific processing enzymes, 655
- UBR1, 656
- UCH, 655, 658
- UCH-L1, 658, 669
 - mutation in mouse, 668
- Un-translated region (UTR), 170, 181, 182, 184, 189
- Unverricht-Lundborg disease, 603
- UPS, 654–656, 658–660
- USP14, 670
 - mutation in mouse, 668
- Vascular dementia, 605
- Vasoactive intestinal peptide (VIP), 674–677
- Voltage-gated Ca²⁺ channels
 - Ca²⁺ translocation across the plasma membrane, 450
 - L-type channels, 450
 - membrane depolarizations, 450
 - Na⁺/K⁺-ATPase, 449, 450
 - transmembrane ionic gradients, 450
 - T-type channels, 450
- Voltage-gated ion channels, 449
 - alteration in membrane potential, 450
 - conformational changes, 450
 - voltage-dependent activation, 450
- von Willebrand factor Proteinase, 567
- WAVE, actin polymerization promoting activity of, 231